Nobuaki Sato

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 854 citations

End-of-study Results, Breast Oncology, Medicine +8

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 404 citations · Full text

Breast Oncology, Overall Survival, Medicine +7

Expression and localization of aquaporins in rat gastrointestinal tract

Yu Koyama, Tadashi Yamamoto, Tatsuo Tani et al. · American Journal of Physiology-Cell Physiology · 1999 · 185 citations

Hypothalamic corticotropin-releasing hormone is a mediator of the anorexigenic effect of leptin.

Yutaka Uehara, Hiroyuki Shimizu, K Ohtani et al. · Diabetes · 1998 · 183 citations

Nutrition, Hypothalamic Corticotropin-releasing Hormone, Neuroendocrinology +24